Neuralstem Inc (NASDAQ:CUR) issued its financial report for the three month periods closed September 30, 2017. Rich Daly, the Chairman and CEO, expressed that they continue to assess the full Phase II data set for NSI-189 to decide the optimal advancement course in MDD and for other problems, including Angelman’s Syndrome after highly promising preclinical […]